Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis

Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis

Background: Pramipexole is a dopamine full agonist approved for the treatment of Parkinson’s disease and restless legs syndrome. Its high affinity for the D3 receptor and neuroprotective, antioxidant, and anti-inflammatory activity provides a rationale for the treatment of depression. In this paper,...

Full description

Bibliographic Details
Main Authors: Antonio Tundo, Sophia Betro’, Rocco de Filippis, Fulvia Marchetti, Daniele Nacca, Roberta Necci, Marica Iommi
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Life
Subjects:
pramipexole
treatment resistant depression
bipolar depression
unipolar depression
dopamine agonists
systematic review
Online Access:https://www.mdpi.com/2075-1729/13/4/1043

Internet

https://www.mdpi.com/2075-1729/13/4/1043

Similar Items